ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / BWAY / news
CERS (27) SSII (30) RCEL (46) DCTH (59) ⌘ Pro Terminal →

Why BWAY Stock dropped -2.38% Today — RQD Quant Desk Flash

$11.09 -2.38% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $11.02

BrainsWay Ltd. (BWAY) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $455.9M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BWAY Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is BWAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, BrainsWay Ltd. (NASDAQ: BWAY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.09 (-2.38% 1D, market cap $455.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BWAY ranks #391 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does BWAY compare to CERS and SSII in the Health Care sector?
▼

Within the Health Care sector (Medical/Dental Instruments), BWAY carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CERS (Cerus Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -15.5%, cap $459.5M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, BWAY leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BWAY?
▼

For BrainsWay Ltd. (BWAY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #391 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $11.02 (-0.62%)🧬 Disciplined Float (-0.40% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERSELL / AVOID • D
025507510044
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D
Cash (12)Whales (4)SEC (13)Macro (6)CEO (9)
Each axis scored 0–20
12M PRICE TARGET CONE-6.3% Base Target
$18 Bull$10 Base$8 Bear
📬 FREE BWAY RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BWAY)Realized 20D OHLCV Swing Band: ±8.1%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY BWAY SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+13/20 pts (30% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 7/9

▲ #2 Bullish Driver: Cash Engine Quality+12/20 pts (27% of score)

SEC XBRL Trailing 12 Months: 0.3% FCF Margin ($12.8M FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Whale & Options Positioning4/20 pts (-16 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-16 pts vs max)

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
52
Grade C-$11.92+0.9% Next Q
Q2 (-2Q)
49
Grade D$12.03-3.3% Next Q
Q3 (-1Q)
47
Grade D$11.63-4.6% Next Q
Current
44
Grade D$11.09-6.5% Hist 90D α
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BWAY Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BWAY currently carries a cautious 44/100 (D) rating due to Whale & Options Positioning (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.84) and Max Pain ($11.64) forces dealer call-delta covering toward $18.27.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Disciplined Float (-0.40% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BWAY• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BWAY Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 44%NO 56%Trade / Inspect Odds →
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →

Why BWAY Stock dropped -2.38% Today — RQD Quant Desk Flash

BrainsWay Ltd. (BWAY) dropped -2.38% to $11.09, trading at 38% of its 52-week range ($7.14 – $17.4). Stretched risk/reward at current multiples (steady margins) under elevated 10-year interest-rate pressure.

  • ▸Technical Tape: Trading at 38% of its 52-week range ($7.14 – $17.4) with RSI-14 at 42.6 (NEUTRAL RANGE).
  • ▸Volatility Profile: Historical 20-day realized swing band of ±8.1% around $11.09 (no active unusual options sweep snapshot on file).
  • ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $12.8M annual free cash flow.
Live BWAY Headlines & Catalysts
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BWAY)

  • ✓Walkthrough of BWAY's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
BWAY // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -32.46%🛡️ HOLDING TREND SUPPORT
2026-11-03O $11.93H $11.93L $11.09C $11.09VOL 123.9K
RES: $17.45SUP: $10.80SMA50: $12.84SMA200: $13.92
$17.92$15.75$13.59$11.42$9.25RES $17.45SUP $10.80$11.092026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BWAY Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BWAY Butterfly Map → + Track BWAY →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on BWAY today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BWAY. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BWAY today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BWAY)

Health Care Rank #391 of 1015 ⚔️ CERS vs BWAY Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BWAY vs. CERS, SSII, RCEL, DCTH)

Industry: Medical/Dental Instruments (120 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, BrainsWay Ltd. (BWAY) ranks #391 by composite RQD confidence (44/100, grade D) and #458 by equity capitalization ($455.9M). Within this direct 5-issuer industry benchmark cohort, BWAY leads on earnings valuation at N/A trailing P/E, while DCTH leads on capital efficiency and profitability with 0.8% ROIC and 86.2% gross margin. DCTH currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with BWAY at 44/100 (D).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BWAY ACTIVE
BrainsWay Ltd.
D 44/100 — — — -2.38% $455.9M Benchmark Subject
CERS
Cerus Corporation
E 27/100 — — -15.5% +3.51% $459.5M /cers-vs-bway →
SSII
SS Innovations International Inc.
E 30/100 — 46.0% -18.5% -1.70% $471.1M /ssii-vs-bway →
RCEL
Avita Medical Inc.
D 46/100 — 82.1% -35.0% -1.53% $484.0M /rcel-vs-bway →
DCTH
Delcath Systems Inc.
C- 59/100 — 86.2% 0.8% +1.78% $487.2M /dcth-vs-bway →

2. BWAY Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

BrainsWay Ltd. (BWAY) operates in Medical/Dental Instruments (Health Care) with an equity capitalization of $455.9M, trailing P/E of N/A, forward P/E of N/A, and EV/EBITDA of N/A. Operating profitability registers a gross margin of —, operating margin of —, net profit margin of —, ROIC of —, and free cash flow yield of —, alongside an Altman Z-Score of N/A and Piotroski F-Score of N/A.

3. BWAY Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BWAY stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, BrainsWay Ltd. (NASDAQ: BWAY) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $11.09 (-2.38% 1D, market cap $455.9M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 13/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 9/20. Across 1015 tracked Health Care issuers, BWAY ranks #391 in composite RQD confidence.

How does BWAY compare to CERS and SSII in the Health Care sector?

Within the Health Care sector (Medical/Dental Instruments), BWAY carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, CERS (Cerus Corporation) holds a E grade (27/100 RQD, P/E N/A, ROIC -15.5%, cap $459.5M) and SSII (SS Innovations International Inc.) posts a E grade (30/100 RQD, P/E N/A, ROIC -18.5%, cap $471.1M). Among the 5-stock peer group, BWAY leads on earnings multiple (N/A) while DCTH leads on capital efficiency (0.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BWAY?

For BrainsWay Ltd. (BWAY), key quantitative strengths include Established market leader in Health Care with deep daily trading liquidity and sector rank #391 in Health Care, while primary risk factors center on Company executives have done more routine share selling than personal cash buying lately and Sensitive to high interest rates and tighter Federal Reserve market liquidity.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BWAY trading relative to its 50-day, 200-day, and 52-week technical levels?

BWAY last traded at $11.09 (-2.38% on volume of 77,650 shares), positioning the stock -13.63% below its 50-day simple moving average ($12.84) and -20.33% below its 200-day simple moving average ($13.92). Across its 52-week range of $7.14 to $17.40, BWAY sits at the 38.5% percentile with a 14-day RSI of 42.6 (NEUTRAL RANGE) and an implied next-earnings move of ±8.1% ($10.19 to $11.99).

Direct Sub-Reports: BWAY RQD Cockpit BWAY 12M Forecast BWAY Earnings & Move BWAY Dividends & DRIP BWAY Insiders & 13F BWAY Whale Options BWAY Profit Sankey BWAY News & Why
ROARABLE RATING BRIEF • RQD 44/100 (D) ✓ SEC XBRL & RQD VERIFIED

BWAY — BrainsWay Ltd.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

BrainsWay Ltd. (BWAY) earns a live Roarable RQD composite score of 44/100, corresponding to a D letter grade (Roarable Sell) at a spot price of $11.09 (-2.38% 1D, market capitalization $455.9M).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of —, gross margin of —, operating margin of —, and free cash flow yield of —.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (9/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (13/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of N/A, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

— BrainsWay Ltd. Is listed on NASDAQ and classified under the Health Care sector and Medical/Dental Instruments industry, with a market capitalization of $0.5B per the company profile. A news item references orders for brain stimulation systems from a Southern California provider, and another references a partner linked to 27 clinics on mental-health treatment access, but these headlines do not establish the full product or revenue model.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (D • RQD 44/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $7.14 – $17.40 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream suppliers, downstream customers, and sector correlations therefore cannot be identified from the provided data. The only ripple-relevant reference is the Macro Regime Fit pillar's note on sector sensitivity, which is not quantified in the source.

  • Key Question #1: Can BWAY sustain or expand its — operating margin and — ROIC against Medical/Dental Instruments peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (— FCF yield) strengthen balance-sheet liquidity (Altman Z-Score N/A) toward the $17.40 52-week high?
  • Key Question #3: How sensitive is BWAY's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

BWAY Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BrainsWay Ltd. (BWAY) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to BWAY Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BWAY Bull vs. Bear Conversation Board — What's Your Call at $11.09?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BWAY 🐻 33% BEARISH CONVICTION
1. Pick Your Side on BWAY:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
BR BreakoutHunter RQD DEBATE OPENER • Swing & Catalyst Trader 🐂 BULLISH 🎯 Target: $14.31 (+26.0%)
📌 Pinned Debate

The Forensic Balance Sheet pillar scores 13/20 with an Altman Z of 2.5 and a Piotroski F of 6/9, and Debt/Equity is 0.5, indicating com

Long BWAY at $11.36 targeting $14.31. The Forensic Balance Sheet pillar scores 13/20 with an Altman Z of 2.5 and a Piotroski F of 6/9, and Debt/Equity is 0.5, indicating comparatively sound balance-sheet metrics.. Institutional whale score is 4/20 and the risk/reward vs. the $7.14 52-week low is skewed heavily in favor of bulls.

VolSurface_Trader 🐂 BULL

@CreditSpread_Watch Shorting a 4/20 institutional whale-flow stock at $11.36 is dangerous when funds are rotating into Health Care.

CR CreditSpread_Watch RQD DEBATE OPENER • Balance Sheet Analyst 🐻 BEARISH 🎯 Target: $9.09 (-20.0%)
Spot @ $11.36

ROIC and FCF yield are both 0% and all margins are 0%, while the Whale 13F Flow pillar scores only 6/20, showing weak cash generation a

Fading this rally in BWAY at $11.36. ROIC and FCF yield are both 0% and all margins are 0%, while the Whale 13F Flow pillar scores only 6/20, showing weak cash generation and institutional conviction.. With a beta of 1.0 and the stock sitting at $11.36 (52-wk range $7.14–$17.40), the easy multiple expansion is already priced in.

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%